Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases.
Limited growth with imperfect balance sheet.
Share Price & News
How has Inovio Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GBMB's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: GBMB underperformed the German Biotechs industry which returned 10% over the past year.
Return vs Market: GBMB underperformed the German Market which returned 12.8% over the past year.
Price Volatility Vs. Market
How volatile is Inovio Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Inovio Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate GBMB's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate GBMB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: GBMB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: GBMB is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GBMB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GBMB is overvalued based on its PB Ratio (11x) compared to the DE Biotechs industry average (3.5x).
How is Inovio Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GBMB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GBMB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GBMB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GBMB's revenue (58% per year) is forecast to grow faster than the German market (5.2% per year).
High Growth Revenue: GBMB's revenue (58% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GBMB's Return on Equity is forecast to be high in 3 years time
How has Inovio Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GBMB is currently unprofitable.
Growing Profit Margin: GBMB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GBMB is unprofitable, and losses have increased over the past 5 years at a rate of -26.9% per year.
Accelerating Growth: Unable to compare GBMB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GBMB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: GBMB has a negative Return on Equity (-319.41%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Inovio Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: GBMB's short term assets ($98.8M) exceed its short term liabilities ($19.5M).
Long Term Liabilities: GBMB's short term assets ($98.8M) exceed its long term liabilities ($95.9M).
Debt to Equity History and Analysis
Debt Level: GBMB's debt to equity ratio (194%) is considered high.
Reducing Debt: Insufficient data to determine if GBMB's debt to equity ratio has reduced over the past 5 years.
Inventory Level: GBMB has a low level of unsold assets or inventory.
Debt Coverage by Assets: GBMB's debt is covered by short term assets (assets are 1.4x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GBMB has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: GBMB has less than a year of cash runway if free cash flow continues to reduce at historical rates of -29.5% each year
What is Inovio Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate GBMB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate GBMB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GBMB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GBMB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GBMB's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
J. Kim (50yo)
Dr. J. Joseph Kim, Ph.D has been the Chief Executive Officer of Inovio Pharmaceuticals, Inc. (alternate name: Inovio Biomedical Corp) since June 1, 2009 and has been its President since October 6, 2009. Dr ...
CEO Compensation Analysis
Compensation vs Market: J.'s total compensation ($USD3.08M) is above average for companies of similar size in the German market ($USD802.74K).
Compensation vs Earnings: J.'s compensation has been consistent with company performance over the past year.
|CEO, President & Director||10.7yrs||US$3.08m||2% $7.0m|
|Chief Financial Officer||17.7yrs||US$1.33m||0.11% $391.7k|
|COO & Executive VP||0.9yrs||no data||no data|
|Chief Scientific Officer & Executive VP||1.3yrs||no data||0.050% $173.5k|
|Director of Investor Relations||2.2yrs||no data||no data|
|Vice President of Communications & Strategic Relations||0.4yrs||no data||no data|
|Senior Vice President of Quality Assurance||0yrs||no data||no data|
|Senior Vice President of Clinical Operations & Global Integration||0yrs||no data||no data|
|Senior Vice President of Regulatory Affairs||0yrs||no data||no data|
|Senior Vice President of Engineering Development||0yrs||no data||no data|
Experienced Management: GBMB's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
|CEO, President & Director||10.7yrs||US$3.08m||2% $7.0m|
|Independent Director||2.2yrs||US$138.80k||0.016% $56.4k|
|Independent Director||1.1yrs||no data||0.0040% $14.1k|
|Chairman of Board of Directors||1.1yrs||US$151.30k||0.043% $150.4k|
|Chairman of the Scientific Advisory Board & Director||20.1yrs||US$447.64k||0.79% $2.7m|
|Member of Scientific Advisory Board||10.7yrs||no data||no data|
|Independent Director||7.7yrs||US$136.55k||0.067% $233.0k|
|Independent Director||0.9yrs||no data||no data|
|Member of Scientific Advisory Board||7.9yrs||no data||no data|
|Member of Scientific Advisory Board||1.3yrs||no data||no data|
Experienced Board: GBMB's board of directors are considered experienced (4.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: GBMB insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.2%.
Inovio Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Inovio Pharmaceuticals, Inc.
- Ticker: GBMB
- Exchange: DB
- Founded: 1979
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$379.597m
- Listing Market Cap: US$349.457m
- Shares outstanding: 101.36m
- Website: https://www.inovio.com
Number of Employees
- Inovio Pharmaceuticals, Inc.
- 660 West Germantown Pike
- Suite 110
- Plymouth Meeting
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|INO||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||May 1992|
|GBMB||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 1992|
Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system’s tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillomavirus-caused pre-cancers and cancers; glioblastoma multiforme; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include The Wistar Institute; University of Pennsylvania; GeneOne Life Science Inc.; ApolloBio Corporation; Regeneron Pharmaceuticals, Inc.; Genentech, Inc.; Plumbline Life Sciences, Inc.; Drexel University; National Institute of Allergy and Infectious Diseases; United States Military HIV Research Program; U.S. Army Medical Research Institute of Infectious Diseases; National Institutes of Health; HIV Vaccines Trial Network; Defense Advanced Research Projects Agency; the Parker Institute for Cancer Immunotherapy; QIAGEN N.V.; Coalition for Epidemic Preparedness Innovations; and Beijing Advaccine Biotechnology Co. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/23 22:34|
|End of Day Share Price||2020/02/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.